問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

Division of Thoracic Medicine

List

185Cases

2016-01-01 - 2019-05-31

Phase III

A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

  • Condition/Disease

    uncontrolled severe asthma

  • Test Drug

    QAW039

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

許武輝醫師
China Medical University Hospital

Division of Thoracic Medicine

2016-01-01 - 2019-12-31

Phase I

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

  • Condition/Disease

    ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

  • Test Drug

    LDK378

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2013-07-09 - 2024-01-07

Phase III

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

  • Condition/Disease

    Non small cell lung cancer

  • Test Drug

    LDK378

Participate Sites
7Sites

Terminated7Sites

2013-09-10 - 2015-10-31

Phase III

A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD

  • Condition/Disease

    moderate to very severe COPD

  • Test Drug

    QVA149

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

徐武輝
China Medical University Hospital

Division of Thoracic Medicine

2016-02-22 - 2022-12-22

Phase II

A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    INC280

Participate Sites
6Sites

Recruiting5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2010-09-01 - 2012-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-03-01 - 2014-12-31

Phase III

A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/ fluticasone propionate in COPD patients with moderate to severe airflow limitation.

  • Condition/Disease

    COPD

  • Test Drug

    NVA237

Participate Sites
9Sites

Terminated9Sites

2012-06-15 - 2013-02-28

Phase III

A 12-week treatment, randomized, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients with chronic obstructive pulmonary disease (COPD)

  • Condition/Disease

    COPD

  • Test Drug

    NVA237

Participate Sites
7Sites

Terminated7Sites

2009-05-01 - 2011-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-11-16 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting1Sites

Terminated12Sites

1 14 15 16 17 18 19
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB